An investigation for investors in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares over potential securities laws violations was announced and NYSE:VRX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 04/11/2016 --An investigation for shareholders who purchased shares ofValeant Pharmaceuticals Intl Inc (NYSE:VRX) in the March 18, 2015 Secondary Offering at $199.00 per share, was announced concerning over potential securities laws violations in connection with the March 18, 2015 Secondary Offering.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) declined from $262.52 per share in August 2015 to as low as $25.98 per share on March 21, 2016.

Investors who purchased shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in the March 18, 2015 Secondary Offering at $199.00 per share, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements in connection with the March 18, 2015 Secondary Offering were materially false and misleading at the time they were made.

On October 2, 2015, a report titled "Citron Research Exposes the Information that Congress Will Find if it Subpoenas Valeant" was published. The report references the United States Congress's reportedly failed attempt to obtain documents from Valeant Pharmaceuticals Intl Inc that would justify the 525% and 212% price increases on two drugs Valeant Pharmaceuticals Intl Inc had acquired rights to, saying the requested information was "highly proprietary and confidential."

On October 14, 2015, Valeant Pharmaceuticals Intlresponded to a letter from Senator Claire McCaskill (D-MO) concerning the company's products Nitropress and Isuprel. Valeant Pharmaceuticals Intl said that in his response to Senator McCaskill, J. Michael Pearson, the chairman of the board and chief executive officer of Valeant Pharmaceuticals Intl, addressed the history of Nitropress and Isuprel, the reimbursement process for hospital procedures involving Nitropress and Isuprel, the analysis and reasons underlying Valeant's pricing decisions, and Valeant's programs designed to improve patient access, among other topics.

In addition, Valeant Pharmaceuticals Intl disclosed that it recently received a subpoena from the U.S. Attorney's Office for the District of Massachusetts and a subpoena from the U.S. Attorney's Office for the Southern District of New York. Most of the materials requested by the subpoenas relate to documents with respect to our patient assistance programs, and also include requests relating to financial support provided by the company for patients, distribution of the company's products, information provided to theCenters for Medicare and Medicaid Services, and pricing decisions.

On October 19, 2015, Valeant Pharmaceuticals Intl reported its third quarter 2015 financial results.

The plaintiff claims that on the same day, Valeant Pharmaceuticals Intl hosted an earnings call during which, for the first time, defendants revealed the previously undisclosed and direct relationship between Valeant Pharmaceuticals Intl and certain specialty pharmacies.

On October 21, 2015, a report was issued entitled "Could this be the Pharmaceutical Enron?". Among other things, the report claims that Valeant Pharmaceuticals Intl utilizes a specialty pharmacy to facilitate drug sales to patients. The same report continued, stating that "Citron believes the whole thing is a fraud to create invoices to deceive the auditors and book revenue. PHANTOM ACCOUNTS."

On October 22, 2015, a lawsuit was filed against Valeant Pharmaceuticals Intl Inc over alleged securities laws violations. The plaintiff claims that the defendants made allegedly false and misleading statements and/or allegedly failed to disclose adverse information about Valeant Pharmaceuticals' business and prospects, including that Valeant Pharmaceuticals was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs, that Valeant Pharmaceuticals's undisclosed use of specialty pharmacies left it subject to increased regulatory risks, and that without the use of the specialty pharmacies, Valeant Pharmaceutical' financial performance and financial guidance between February 23, 2015 and October 20, 2015 would have been negatively impacted, and that as a result of these false and misleading statements and/or omissions, Valeant Pharmaceuticals stock traded at artificially inflated prices between February 23, 2015 and October 20, 2015, reaching over $260 per share.

On February 22, 2016, Valeant announced that it would restate its 2014 and 2015 financial results.

On February 29, 2016, Valeant disclosed that the SEC is investigating the Company.

Then, on March 15, 2016, Valeant cut its 2016 revenue forecast and disclosed that its delay in filing an annual report could mean a default on its $30 million debt.

Those who purchased shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com